Unequal access: the prohibitive costs of new drugs in low- and middle-income countries

Abstract

The prohibitive costs of new pharmacological agents, particularly biologicals, have largely limited their use to high-income countries, resulting in widening of health disparities. Urgent action from the pharmaceutical industry, governments and healthcare organizations is needed to improve access to treatment and address these inequities.